Ipratropium Nebules bulk supplier for pharma manufacturers

Ipratropium Nebules Suppliers & Bulk Manufacturers

Available Forms: Nebulizer Solution

Available Strengths: 250 mcg/2 mL, 500 mcg/2 mL

Reference Brands: Atrovent(US & EU)

Category: Critical Care

Ipratropium Nebules is available in Nebulizer Solution and strengths such as 250 mcg/2 mL, 500 mcg/2 mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Ipratropium Nebules is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Technical Specifications & Supply Details
Lead Time 7 to 60 days (depending on batch size & schedule)
MOQ As per manufacturer’s batch size
COA Available with every batch
Regulatory Dossier / DMF Available upon request
Export Documentation FSC, COA, Manufacturing License, Product Permission
Standards IP, BP, USP
Certifications WHO-GMP, EU-GMP, USFDA (as applicable)

Ipratropium Nebules can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Product Description: Ipratropium Nebules are inhalation solutions used via nebulizer to treat chronic obstructive pulmonary disease (COPD), bronchitis, and asthma. These anticholinergic bronchodilators are commonly available in unit-dose formats like 250 mcg/2 mL and 500 mcg/2 mL, as well as in multi-dose vials (0.025–0.05%). In the US, Ipratropium is marketed as Atrovent by Boehringer Ingelheim and via generics by Teva and Nephron. In the EU, Atrovent and its equivalents are produced by Sandoz, Teva, and Stada. Pharma B2B platforms ensure consistent supply of Ipratropium Nebules for hospitals, clinics, and respiratory therapy centers treating obstructive airway disorders.

Frequently Asked Questions

Yes, Ipratropium Nebules is available with DMF and other regulatory documents such as COA and MSDS. These can be provided upon request for qualified buyers.

Absolutely. Sample requests are accepted for formulation trials and quality checks. Please submit an enquiry to initiate the process.

Our manufacturing partners are GMP-certified and comply with ISO and WHO standards, ensuring global quality benchmarks.

Lead times vary based on quantity and destination, but most orders are fulfilled within 1–3 weeks. Express shipping options are available.

Yes, Ipratropium Nebules is exported to over 30 countries across Asia, Africa, Europe, and Latin America. We support documentation for customs and regulatory clearance.

Related Products

Glucagon

Strength:
1 mg lyophilized powder for reconstitution (IM/SC/IV)

Form: Intramuscular (IM), Subcutaneous (SC), and Intravenous (IV) injection

Reference Brands: Glucagen®, Gvoke®,Baqsimi®(US); Glucagen® Hypokit(EU)

View Details
Insulin (Iv)

Strength:
100 units/mL (U-100) in 10 mL vials

Form: Intravenous (IV) solution

Reference Brands: Humulin® R, Novolin® R(US); Actrapid®, Humulin® R, Insuman® Rapid(EU)

View Details
Flumazenil

Strength:
0.1 mg/mL in 5 mL or 10 mL vials

Form: Intravenous (IV) injection

Reference Brands: Romazicon®(US), Anexate®(EU)

View Details
Naloxone

Strength:
0.4 mg/mL in 1 mL/10 mL vials, 1 mg/mL in 2 mL prefilled syringes

Form: Intravenous (IV) injection/IM/SQ

Reference Brands: Narcan® (US); Narcan® (EU)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.